Abstract
Background: The purpose of this manuscript is to report the direct effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer-patients with peritoneal metastasis (PM). Materials and Methods: Thirty-five patients with PM were enrolled, and were treated with neoadjuvant laparoscopic HIPEC (LHIPEC). LHIPEC was performed at 42 to 43 centigrade for 60 minutes adding 3 liter of saline plus 12.5mg/m2 of Mitomycin C with Cisplatin (50mg/m2). Second session of LHIPEC was done one month after the first LHIPEC in all cases. At the second session of LHIPEC, ascites volume, peritoneal cytology and peritoneal cancer index (PCI) were examined again. Results: Intraoperative complications of bowel injury were experienced in one and three at 1st and 2nd session of laparoscopy, respectively. There was no mortality after LHIPEC. Ascites was completely disappeared in 17 of 34 patients at the second session of laparoscopy. PFCCs had been detected in 28 (80.0%) patients at the 1st session, and the positive cytology changed to be negative in 16 (57.1%) of 28 patients at the second session. PCI at the 2nd session (12.5 ± 10.5) was significantly lower than that at the 1st session (16.8 ± 9.6) (P=0.023). PCI levels at the 2nd session changed to be 0 in 6 patients. Conclusion: This new method is not only a safe and convenient method for predicting feasibility of complete cytoredution, but also an effective treatment to control malignant ascites and to eradicate PFCCs before cytoreductive surgery. Furthermore, LHIPEC can reduce PCI levels.
Highlights
Peritoneal metastasis (PM) from gastric cancer has previously been considered a terminal disease
The purpose of this manuscript is to report the direct effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer-patients with peritoneal metastasis (PM)
This study demonstrate a benefit of laparoscopic HIPEC (LHIPEC) with number of important findings such as the correct evaluation of peritoneal cancer index (PCI), decreased/disappeared ascites, induction of the disappearance of peritoneal free cancer cells (PFCCs) and decreased PCI levels in patients with PM from gastric cancer
Summary
Peritoneal metastasis (PM) from gastric cancer has previously been considered a terminal disease. A more aggressive treatment strategy called cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has been developed with curative intent (Yonemura et al, 2005). CRS and HIPEC are widely accepted as standard of care to achieve long-term survival in patients with PM from colorectal carcinoma, appendiceal cancer and diffuse malignant peritoneal mesothelioma (Verwaal, 2009; Piso et al, 2001; Yan, Welch, Black, & Sugarbaker, 2009). Yang et al (2011) reported CRS and HIPEC improved survival of patients with PM from gastric cancer by a phase III randomized clinical trial. HIPEC is not still as a standard care for peritoneal metastasis from gastric www.ccsenet.org/cco. The purpose of this manuscript is to report the direct effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer-patients with peritoneal metastasis (PM)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.